Gachon University Gil Medical Cneter
Welcome,         Profile    Billing    Logout  
 3 Trials 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lee, Kyung Hee
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
FROST, NCT05179889: Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer

Enrolling by invitation
2/3
308
RoW
mFOLFIRINOX, mFOLFOX 6
Chungnam National University Hospital, Boryung Pharmaceutical Co., Ltd
Colon Cancer Stage III
03/25
03/28
SOLAR, NCT05673772: Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer

Recruiting
2
364
RoW
short-course radiotherapy, mFOLFOX6, Chemoradiotherapy, TME surgery
Kyungpook National University Hospital, National Cancer Center, Korea
Rectal Cancer
12/24
12/29
NCT03763604: Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Available
N/A
Europe, Canada, RoW
Abemaciclib, LY2835219
Eli Lilly and Company
Metastatic Breast Cancer
 
 

Download Options